PLx Pharma Q2 Loss Top Estimates, But Revenues Miss; Stock Down 15%

PLx Pharma Inc. (PLXP) reported Friday a second-quarter net loss attributable to common shareholders of $11.56 million or $0.43 per share, narrower than $18.71 million or $0.79 per share in the prior-year quarter.

Excluding items, adjusted loss for the quarter were $0.52 per share, compared to adjusted loss of $0.27 per share in the year-ago quarter.

Total revenues for the quarter were $0.48 million, compared to nil in the same quarter last year.

On average, three analysts polled by Thomson Reuters expected the company to report a loss of $0.56 per share on revenues of $3.5 million for the quarter. Analysts' estimates typically exclude special items.

The company said it has recently engaged Raymond James & Associates, Inc. as financial advisor to commence a formal process to evaluate strategic alternatives to enhance stockholder value with the full support from the Board.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Activity in the U.S. manufacturing sector slowed by more than expected in the month of September but still saw continued growth, according to a report released by the Institute for Supply Management on Monday. Stocks have moved sharply higher in morning trading on Monday, regaining ground following a dismal September. The major averages have all shown substantial moves to the upside. Swedish geneticist Svante Paabo has won this year's Nobel Prize in Physiology/Medicine for his discoveries concerning the genomes of extinct hominins and human evolution. Through his pioneering research, Svante Pääbo accomplished something seemingly impossible: sequencing the genome of the Neanderthal, an extinct relative of present-day humans. He also made the sensational discovery of a previous
Follow RTT